Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.
Most patients with chronic lymphocytic leukemia are diagnosed at an early stage, when traditional staging systems fail to distinguish those with an aggressive disease course from those with an excellent prognosis. This failure underscores the need for better prognostic markers. Although many markers have been explored, this review focuses on the newer and most clinically relevant markers: cytogenetic aberrations, zeta-associated protein 70, immunoglobulin mutational status, and CD38 expression. Although these markers have been shown to predict outcomes for groups of patients, individual patients may have a variable course; therefore, the outcome for any one patient remains hard to predict. To date, no study has shown a benefit from early cytotoxic therapy for any subgroup of patients with chronic lymphocytic leukemia.
Jain
Nitin
N
Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Lamanna
Nicole
N
D051997:ADP-ribosyl Cyclase 1 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002869:Chromosome Aberrations; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011379:Prognosis; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000378:metabolism
D014408:Biomarkers, Tumor; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D051746:ZAP-70 Protein-Tyrosine Kinase; D051997:ADP-ribosyl Cyclase 1
Proc Natl Acad Sci U S A. 1989 Aug;86(15):5913-7
2503826
N Engl J Med. 2000 Dec 28;343(26):1910-6
11136261
Immunol Today. 1994 Jun;15(6):288-94
7520700
Br J Haematol. 1996 Feb;92(2):382-8
8603004
Blood. 2002 Feb 1;99(3):1023-9
11807008
Blood. 2002 Aug 15;100(4):1410-6
12149225
Blood. 2009 Apr 2;113(14):3168-71
19050308
J Clin Oncol. 2009 Feb 1;27(4):491-7
19075280
Blood. 2005 Nov 1;106(9):3175-82
16014569
Blood. 1997 Apr 1;89(7):2516-22
9116297
J Clin Oncol. 2007 Dec 10;25(35):5616-23
17984186
Ann Hematol. 2003 Dec;82(12):759-65
14551737
Blood. 1999 Sep 15;94(6):1840-7
10477712
Blood. 1997 Jun 1;89(11):4153-60
9166858
J Clin Oncol. 2006 Oct 1;24(28):4634-41
17008705
J Clin Oncol. 2007 Mar 1;25(7):799-804
17283363
Blood. 2001 Nov 1;98(9):2633-9
11675331
Blood. 1975 Aug;46(2):219-34
1139039
Blood. 2003 Jun 15;101(12):4944-51
12595313
J Clin Oncol. 2003 Nov 1;21(21):3928-32
14581416
Blood. 1995 Mar 15;85(6):1580-9
7888675
J Clin Oncol. 2006 Jan 20;24(3):437-43
16344317
Blood. 2008 Sep 1;112(5):1923-30
18577710
Leukemia. 2005 May;19(5):750-8
15759031
Cancer. 2009 Jan 15;115(2):373-80
19117034
Blood. 2001 Mar 15;97(6):1902-3
11263445
Leukemia. 2004 Mar;18(3):476-83
14712287
Blood. 1993 Dec 1;82(11):3452-9
8241511
Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68
17707833
Leukemia. 1997 Nov;11(11):1929-32
9369428
Cancer. 1977 Aug;40(2):855-64
890666
Am J Hematol. 1998 Nov;59(3):223-9
9798660
Br J Haematol. 1990 Nov;76(3):352-8
2261345
Blood. 2003 Mar 1;101(5):2049-53
12411304
N Engl J Med. 2003 May 1;348(18):1764-75
12724482
Clin Cancer Res. 2009 Feb 1;15(3):995-1004
19188171
Lancet. 2007 Jul 21;370(9583):230-239
17658394
Blood. 2001 Jul 1;98(1):181-6
11418478
N Engl J Med. 2004 Aug 26;351(9):893-901
15329427
Blood. 2008 Aug 15;112(4):975-80
18411418
Leukemia. 1995 Dec;9(12):2003-8
8609709
Blood. 2008 Oct 15;112(8):3322-9
18689542
Leuk Lymphoma. 2007 Feb;48(2):311-20
17325891
Blood. 1999 Sep 15;94(6):1848-54
10477713
Blood. 2004 May 1;103(9):3278-81
14726385
N Engl J Med. 2002 Aug 8;347(6):452-3
12167696